REFERENCES

  1. NICE Guidelines (2004). Improving Supportive Palliative Care for Adults with Cancer.
  2. Wooldridge JE et al (2001). Corticosteroids in advanced cancer. Oncology 15:225.
  3. Twycross R, Wilcock A (Eds). Palliative Care Formulary: Fifth. Palliativedrugs.com Ltd 2014.
  4. Committee on Safety of Medicines and Medicines Control Agency Expert Working Group. Withdrawal of systemic corticosteroids. Current Problems in Pharmacovigilance 1998: 24 (May) 5.
  5. Piper JM et al (1991). Corticosteroid use and peptic ulcer disease: role of non-steroidal anti-inflammatory drugs. Ann Intern Med 114:735.Joint Formulary Committee (British Medical
  6. Association and Royal Pharmaceutical Company). British National Formulary (BNF 62). bnf.org 2011.
  7. Duggan D E et al (1975). Bioavailability of oral dexamethasone. Clinical Pharmacy and Therapeutics 18(2):205-209.
  8. Back I. (2001). Palliative Medicine Handbook 3rd Ed. BPM Books.
  9. Feuer DDJ, Broadley KE.Corticosteriods for the resolution of malignant bowel obstruction in advanced gynaecological and gastrointestinal cancer (Review). Cochrane Database of Systematic Reviews 2000, Issue 1. Art. No.: CD001219. DOI: 10.1002/14651858.CD001219.

DISCLAIMER

This Guide is intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
While WMPCPS takes every care to compile accurate information , we cannot guarantee its correctness and completeness and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.